Abstract

Radioluminescence microscopy (RLM) is an imaging technique that allows quantitative analysis of clinical radiolabeled drugs and probes in single cells. However, the modality suffers from slow data acquisition (15-30 minutes), thus critically affecting experiments with short-lived radioactive drugs. To overcome this issue, we suggest an approach that significantly accelerates data collection. Instead of using a single scintillator to image the decay of radioactive molecules, we sandwiched the radiolabeled cells between two scintillators. As proof of concept, we imaged cells labeled with [18F]FDG, a radioactive glucose popularly used in oncology to image tumors. Results show that the double scintillator configuration increases the microscope sensitivity by two-fold, thus reducing the image acquisition time by half to achieve the same result as the single scintillator approach. The experimental results were also compared with Geant4 Monte Carlo simulation to confirm the two-fold increase in sensitivity with only minor degradation in spatial resolution. Overall, these findings suggest that the double scintillator configuration can be used to perform time-sensitive studies such as cell pharmacokinetics or cell uptake of short-lived radiotracers.

Highlights

  • Positron emission tomography (PET) is a molecular imaging technique that enables interrogation of biophysical processes in living subjects in a non-invasive manner

  • Experimental results demonstrate that the double scintillator configuration yields significantly higher radioactive decay count

  • Radioluminescence microscopy (RLM) images acquired with the two configurations are shown in Fig 2A and 2B, respectively

Read more

Summary

Introduction

Positron emission tomography (PET) is a molecular imaging technique that enables interrogation of biophysical processes in living subjects in a non-invasive manner It is popularly used in the clinic to diagnose and characterize various diseases such as cancer, cardiovascular disorders, and neurological disorders using a wide range of radiotracers [1,2,3,4], including radioactive glucose 2-deoxy-2-[18F]fluorodeoxyglucose or [18F]FDG. The biological activity of radiopharmaceuticals is difficult to confirm—the spatial resolution of current clinical and pre-clinical imaging systems is limited to the tissue level.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call